Glenn became Chief Scientific Officer in 2025, previously serving as Senior Vice President of Early Development since 2022. He leads internal innovation, overseeing early-stage product development and integrating translational medicine into development, and clinical strategies.

Glenn has over 20 years of industry and research experience and has been involved in numerous programs that leverage cutting-edge biotechnologies to develop new therapies to address unmet medical needs. He has held multiple senior leadership positions in both venture-backed startup and public companies using his expertise and passion to help drive R&D programs to meaningful proof-of-concept and value-inflection.

Glenn received his Ph.D. in Chemistry from the University of Virginia and conducted his postdoctoral training in Molecular Biology at Massachusetts General Hospital/Harvard Medical School in Boston.